Results 91 to 100 of about 15,560 (165)

PET-CT imaging in a patient with progressive supranuclear palsy [PDF]

open access: yes, 2015
Hosp Beneficencia Portuguesa São Paulo, Med Imagem, BR-01323001 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Dept Neurol, São Paulo, SP, BrazilHosp Coracao, São Paulo, SP, BrazilUniversidade Federal de São Paulo, Dept Neurol, São Paulo, SP ...
Amaral, Lazaro Luiz Faria do   +6 more
core   +2 more sources

Reply to “Neurophysiological Testing to Diagnose Stiff‐Person Spectrum Disorder”

open access: yes
Movement Disorders Clinical Practice, EarlyView.
João Moura   +5 more
wiley   +1 more source

Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

open access: yesMovement Disorders, EarlyView.
Abstract Background Clinical progression rate is the typical primary endpoint measure in progressive supranuclear palsy (PSP) clinical trials. Objectives This longitudinal multicohort study investigated whether baseline clinical severity and regional brain atrophy could predict clinical progression in PSP–Richardson's syndrome (PSP‐RS).
Andrea Quattrone   +424 more
wiley   +1 more source

Diagnostic challenges in multiple system atrophy

open access: yesNeuropsychiatric Disease and Treatment, 2018
Diana Obelieniene,1 Sandra Bauzaite,1 Ilona Kulakiene,2 Evaldas Keleras,2 Indre Eitmonaite,3 Daiva Rastenyte1 1Department of Neurology, 2Department of Radiology, 3Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania Abstract ...
Obelieniene D   +5 more
doaj  

Immunotherapy in progressive supranuclear palsy

open access: yesCurrent Opinion in Neurology, 2020
Purpose of review Progressive supranuclear palsy (PSP) is a progressive adult-onset neurodegenerative disease. Abnormally, phosphorylated forms of the microtubule-associated protein tau containing four repeat domains (4R-tau) aggregate in neurons. Additionally, increasing evidence suggests that secretion and uptake of fragments
Pavan A. Vaswani, Abby L. Olsen
openaire   +4 more sources

Amantadine Can Treat Blepharospasm in Levodopa Peak‐Dose Dyskinesia

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Francisco de Assis Aquino Gondim   +4 more
wiley   +1 more source

AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression

open access: yesMovement Disorders, EarlyView.
Abstract Objectives The aim was to evaluate the safety, tolerability, pharmacokinetics, and potential clinical efficacy of AZP2006, an oral pleiotropic drug modulating progranulin levels, in patients with progressive supranuclear palsy (PSP), a rare tauopathy. Methods A randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted at
Jean‐Christophe Corvol   +17 more
wiley   +1 more source

Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease [PDF]

open access: yes, 2005
beta-CIT binding in both caudate nuclei was lower than in the group of patients with IPD. In addition, putamen to caudate binding ratios were higher in the group of APS patients.
A Antonini   +39 more
core   +1 more source

Progressive supranuclear palsy [PDF]

open access: yesNeurology, 2008
In the article, “Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy,” Dr. Borroni and her coauthors ( Neurology ®2008;71:1796–1803) looked at specific medical tests that could help physicians accurately diagnose this illness.
openaire   +2 more sources

A Biomarker‐Based Classification of Corticobasal Syndrome

open access: yesMovement Disorders, EarlyView.
Abstract Background Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau‐predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD).
Carla Palleis   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy